Dr Leypoldt on the Use of Isa-KRd in Newly Diagnosed, High-Risk Multiple Myeloma


Lisa Leypoldt, MD, discusses findings from the phase 2 GMMG-CONCEPT trial in patients with multiple myeloma.

Lisa Leypoldt, MD, clinician and researcher, Department of Oncology, Hematology and Bone Marrow Transplantation with Department of Pneumology, University Medical Center Hamburg-Eppendorf, and a postdoctoral research fellow, Dana-Farber Cancer Institute, discusses findings from the phase 2 GMMG-CONCEPT trial (NCT03104842) in patients with multiple myeloma.

The phase 2 trial evaluated the addition of isatuximab-irfc (Sarclisa) to carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Isa-KRd) in transplant-eligible (n = 127) and transplant-ineligible (n = 26) patients with newly diagnosed multiple myeloma with high-risk disease. High-risk disease was defined as having International Staging System stage II/III risk with deletion 17p, translocation (4;14), or translocation (14;16), or more than three 1q21 copies. Transplant-eligible patients received 6 cycles of Isa-KRd induction before transplant, followed by 4 cycles of Isa-KRd consolidation plus Isa-KR as maintenance therapy for 2 years. Transplant-eligible patients also received high-dose melphalan. Transplant-ineligible patients received an additional 2 cycles of Isa-KRd cycles during induction.

The primary end point of the study was minimal residual disease (MRD) negativity levels below 10−5 per next-generation flow at the end of consolidation. The secondary end point was progression-free survival (PFS), Leypoldt says.

Findings from the interim analysis demonstrated that the MRD-negativity rates after consolidation were 67.7% and 54.2% in transplant-eligible and transplant-ineligible patients, meeting the primary end point of the study, (P = .004; P = .012), respectively. Moreover, 81.8% and 69.2% of transplant-eligible and transplant-ineligible patients achieved MRD negativity at any time point, respectively, Leypoldt says. Moreover, MRD negativity was sustained for more than 1 year in 62.6% and 46.2% of transplant-eligible and transplant-ineligible patients, respectively.

Encouragingly, at a median follow-up of 44 months in transplant-eligible patients and 33 months in transplant-ineligible patients, median PFS and median overall survival were not reached in either arm, Leypoldt says. The 1-, 2-, and 3-year PFS rates were 86.4% (95% CI, 80.5%-92.6%), 78.3% (95% CI, 71.4%-85.9%), and 68.9% (95% CI, 61.2%-77.7%) in transplant-eligible patients and 75.1% (95% CI, 59.7%-94.5%), 62.6% (95% CI, 46.0%-85.3%), and 58.4% (95% CI, 41.7%-81.9%) in transplant-ineligible patients. These outcomes are promising for such a high-risk patient population, Leypoldt concludes.

Related Videos
Peter Schmid, MD, PhD
Seema A. Khan, MD
Stephanie L. Graff, MD
Senthil Damodaran, MD, PhD
Jason Jincong Freeman, PhD
Heather A. Parsons, MD, MPH
Marc J. Braunstein, MD, PhD
Shridar Ganesan, MD, PhD
Patrick Boland, MD